Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press172110.17650/1726-9776-2024-20-2-122-128CLINICAL NOTESКЛИНИЧЕСКИЕ СЛУЧАИWhen repeated biopsy dramatically changes treatment tactics in metastatic castration-refractory prostate cancer with neuroendocrine transformation: clinical case and literature reviewКогда повторная биопсия кардинально меняет тактику лечения при метастатическом кастрационно-рефрактерном раке предстательной железы с нейроэндокринной трансформацией: клинический случай и обзор литературыhttps://orcid.org/0009-0003-8857-3275UsoltsevaI. S.УсольцеваИ. С.
Russian Federation

Inessa Stanislavovna Usoltseva 

3 Gorky St., Yuzhno-Sakhalinsk 693010

                                                                                  

Инесса Станиславовна Усольцева, и.о. зав. дневным стационаром 

693010 Южно-Сахалинск, ул. Горького, 3

inessau1984@gmail.comhttps://orcid.org/0009-0001-5470-0219ParsadanovaE. L.ПарсадановаЭ. Л.
Russian Federation

3 Gorky St., Yuzhno-Sakhalinsk 693010

Эльвира Левоновна Парсаданова, зав. дневным стационаром

693010 Южно-Сахалинск, ул. Горького, 3

2903410@mail.ruKimYu. K.КимЮ. К.
Russian Federation

430 Mira Prospekt, Yuzhno-Sakhalinsk 693004

Юлия Кюнтэевна Ким, заместитель начальника по клинико-экспертной работе, врач-патологоанатом высшей категории 

693004 Южно-Сахалинск, пр-кт Мира, 430

kimyuk.sakh@yandex.ruSakhalin Regional Clinical Oncological DispensaryГБУЗ "Сахалинский областной онкологический диспансер"Sakhalin Regional Pathologoanatomical BureauГБУЗ «Областное патологоанатомическое бюро»190820242021221282009202312072024https://oncourology.abvpress.ru/oncur/article/view/1721

Neuroendocrine neoplasia of the prostate gland is a rather rare neuroendocrine carcinoma characterized by poor prognosis. With an atypical course of prostate adenocarcinoma in certain cases, it is possible to suspect development of secondary neuroendocrine cancer. A timely repeat biopsy and correct diagnosis can affect both the patient’s life expectancy and his quality of life.

Нейроэндокринная неоплазия предстательной железы – достаточно редкая нейроэндокринная карцинома, характеризующаяся неблагоприятным прогнозом. При нетипичном течении аденокарциномы предстательной железы в определенных случаях возможно заподозрить развитие вторичного нейроэндокринного рака. Своевременная повторная биопсия и верный диагноз способны повлиять как на продолжительность, так и на качество жизни пациента.

neuroendocrine cancersmall cell cancerprostate glandclinical the patient’s life expectancy and his quality of lifeanticancer drug therapyнейроэндокринный ракпредстательная железаклиническиере комендациилекарственная терапияAbbas F., Civantos F., Benedetto P., Soloway M.S. Small cell carcinoma of the bladder and prostate. Urology 1995;46(5):617–30. DOI: 10.1016/S0090-4295(99)80290-8Cohen R.J., Glezerson G., Taylor L.F. et al. The neuroendocrine cell population of the human prostate gland. J Urol 1993;150(2 Pt 1): 365–8. DOI: 10.1016/s0022-5347(17)35484-8Abbasova D.V., Polikarpova S.B., Kozlov N.A. et al. Neuroendocrine carcinoma of the prostate (review of the literature). Sovremennaya onkologiya = Journal of Modern Oncology 2019;21(3):52–5. (In Russ.). DOI: 10.26442/18151434.2019.3.190673Аббасова Д.В., Поликарпова С.Б., Козлов Н.А. и др. Нейроэндокринный рак предстательной железы (обзор литературы). Современная онкология 2019;21(3):52–5. DOI: 10.26442/18151434.2019.3.190673Frank G.A., Andreeva Yu.Yu., Moskvina L.V. et al. A new WHO classification of prostate tumors. Arkhiv patologii = Russian Journal of Archive of Pathology 2016;78(4):32–42. (In Russ.) DOI: 10.17116/patol201678432-42Франк Г.А., Андреева Ю.Ю., Москвина Л.В. и др. Новая классификация ВОЗ опухолей предстательной железы. Архив патологии 2016;78(4):32–42. DOI: 10.17116/patol201678432-42Treatment and survival of patients with cancer of the prostate. The Veterans Administration Co-operative Urological Research Group. Surg Gynecol Obstet 1967;124(5):1011–7.Gilani S., Guo C.C., Li-Ning E.M. et al. Transformation of prostatic adenocarcinoma to well-differentiated neuroendocrine tumor after hormonal treatment. Hum Pathol 2017;64:186–90. DOI: 10.1016/j.humpath.2017.01.006Terry S., Beltran H. The many faces of neuroendocrine differentiation in prostate cancer progression. Front Oncol 2014;4:60. DOI: 10.3389/fonc.2014.00060Priemer D.S., Montironi R., Wang L. et al. Neuroendocrine tumors of the prostate: emerging insights from molecular data and updates to the 2016 World Health Organization Classifcation. Endocr Pathol 2016;27(2):123–35. DOI: 10.1007/s12022-016-9421-zНосов Д.А., Волкова М.И., Гладков О.А. и др. Практические рекомендации по лекарственному лечению рака предстательной железы. Злокачественные опухоли: Практические рекомендации RUSSCO 2023;13(3s2):640–60. DOI: 10.18027/2224-5057-2023-13-3s2-1-640-660Nosov D.A., Volkova M.I., Gladkov O.A. et al. Practical guidelines on treatment of prostate cancer. Zlokachestvennie opukholi: Prakticheskie rekomendatsii RUSSCO = Malignant Tumors: RUSSCO Practical Guidelines 2023;13(3s2):640–60. (In Russ.). DOI: 10.18027/2224-5057-2023-13-3s2-1-640-660Aggarwal R., Huang J., Alumkal J.J. et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: A multi-institutional prospective study. J Clin Oncol 2018;36(24):2492–503. DOI: 10.1200/JCO.2017.77.6880Aggarwal R., Huang J., Alumkal J.J. et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: A multi-institutional prospective study. J Clin Oncol 2018;36(24):2492–503. DOI: 10.1200/JCO.2017.77.6880National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Prostate cancer. Version 4.2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdfNational Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Prostate cancer. Version 4.2023. Available at: https://www.nccn.org/professionals/ physician_gls/pdf/prostate.pdfLoriot Y., Massard C., Gross-Goupil M. et al. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann Oncol 2009;20(4):703–8. DOI: 10.1093/annonc/mdn694Loriot Y., Massard C., Gross-Goupil M. et al. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann Oncol 2009;20(4):703–8. DOI: 10.1093/annonc/mdn694Fléchon A., Pouessel D., Ferlay C. et al. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. Ann Oncol 2011;22(11):2476–81. DOI: 10.1093/annonc/mdr004Fléchon A., Pouessel D., Ferlay C. et al. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. Ann Oncol 2011;22(11):2476–81. DOI: 10.1093/annonc/mdr004Caubet M., Dobi E., Pozet A. et al. Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study. Mol Clin Oncol 2015;3(6):1208–12. DOI: 10.3892/mco.2015.628Caubet M., Dobi E., Pozet A. et al. Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study. Mol Clin Oncol 2015;3(6):1208–12. DOI: 10.3892/mco.2015.628Corn P.G., Heath E.I., Zurita A. et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial. Lancet Oncol 2019;20(10):1432–43. DOI: 10.1016/S1470-2045(19)30408-5Corn P.G., Heath E.I., Zurita A. et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial. Lancet Oncol 2019;20(10):1432–43. DOI: 10.1016/S1470-2045(19)30408-5Briasoulis E., Aravantinos G., Kouvatseas G. et al. Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study. BMC Cancer 2013;13:263. DOI: 10.1186/1471-2407-13-263Briasoulis E., Aravantinos G., Kouvatseas G. et al. Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study. BMC Cancer 2013;13:263. DOI: 10.1186/1471-2407-13-263De Bono J.S., Molife L.R., Sonpavde G. et al. Phase II study of eribulin mesylate (E7389) in patients with metastatic castrationresistant prostate cancer stratified by prior taxane therapy. Ann Oncol 2012;23(5):1241–9. DOI: 10.1093/annonc/mdr380De Bono J.S., Molife L.R., Sonpavde G. et al. Phase II study of eribulin mesylate (E7389) in patients with metastatic castrationresistant prostate cancer stratified by prior taxane therapy. Ann Oncol 2012;23(5):1241–9. DOI: 10.1093/annonc/mdr380Michaelson M.D., Bellmunt J., Hudes G.R. et al. Multicenter phase II study of trabectedin in patients with metastatic castrationresistant prostate cancer. Ann Oncol 2012;23(5):1234–40. DOI: 10.1093/annonc/mdr399Michaelson M.D., Bellmunt J., Hudes G.R. et al. Multicenter phase II study of trabectedin in patients with metastatic castrationresistant prostate cancer. Ann Oncol 2012;23(5):1234–40. DOI: 10.1093/annonc/mdr399Yashi M., Nishihara D., Mizuno T. et al. Metronomic oral cyclophosphamide chemotherapy possibly contributes to stabilization of disease in patients with metastatic castrationresistant prostate cancer: a prospective analysis of consecutive cases. Clin Genitourin Cancer 2014;12(5):e197–203. DOI: 10.1016/j.clgc.2014.02.007Yashi M., Nishihara D., Mizuno T. et al. Metronomic oral cyclophosphamide chemotherapy possibly contributes to stabilization of disease in patients with metastatic castrationresistant prostate cancer: a prospective analysis of consecutive cases. Clin Genitourin Cancer 2014;12(5):e197–203. DOI: 10.1016/j.clgc.2014.02.007Aparicio A.M., Harzstark A.L., Corn P.G. et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 2013;19(13):3621–30. DOI: 10.1158/1078-0432.CCR-12-3791Aparicio A.M., Harzstark A.L., Corn P.G. et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 2013;19(13):3621–30. DOI: 10.1158/1078-0432.CCR-12-3791